In Re PEN

CourtCourt of Appeals for the Federal Circuit
DecidedJune 12, 2024
Docket23-2282
StatusUnpublished

This text of In Re PEN (In Re PEN) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re PEN, (Fed. Cir. 2024).

Opinion

Case: 23-2282 Document: 45 Page: 1 Filed: 06/12/2024

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

IN RE: THE PEN, Appellant ______________________

2023-2282 ______________________

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. 16/104,878. ______________________

Decided: June 12, 2024 ______________________

THE PEN, West Hollywood, CA, pro se.

MARY L. KELLY, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, VA, for appellee Katherine K. Vidal. Also represented by KAKOLI CAPRIHAN, WILLIAM LAMARCA, AMY J. NELSON, FARHEENA YASMEEN RASHEED. ______________________ Case: 23-2282 Document: 45 Page: 2 Filed: 06/12/2024

2 IN RE: PEN

Before MOORE, Chief Judge, TARANTO, Circuit Judge, and CECCHI, District Judge. ∗ PER CURIAM. The Pen (Pen) appeals a decision of the Patent Trial and Appeal Board (Board) affirming an Examiner’s rejec- tion of claims 1, 4–6, 10, and 13 of U.S. Patent Application No. 16/104,878 as unpatentable under 35 U.S.C § 112(a) for lack of enablement. We have jurisdiction under 28 U.S.C. § 1295(a)(4). For the reasons discussed below, we affirm. BACKGROUND The ’878 Application is directed to metallole polymers with a polycyclic repeating unit backbone. Independent claim 1 is illustrative of claims at issue: 1. A polycylic metallole heteroatom rich conductive long chain polymer comprised of the repeating unit in the brackets in either formula 2 below, where n is the number of repeating units, M is the heteroa- tom, R is any substituent, and x is the number of R substituents, depicted as

∗ Honorable Claire C. Cecchi, District Judge, United States District Court for the District of New Jersey, sitting by designation. Case: 23-2282 Document: 45 Page: 3 Filed: 06/12/2024

IN RE: PEN 3

or formula 4 below, where n is the number of re- peating units, M is the heteroatom, R is any sub- stituent, and x is the number of R substituents, depicted as

where there are more than eight repeating units, and where the metallole heteroatom is nitrogen. J.A. 132–33. The Examiner issued a final rejection for claims 1, 4– 6, 10, and 13 of the ’878 Application pursuant to 35 U.S.C. § 112(a) for failing to comply with the enablement require- ment. 1 J.A. 142–43. The Examiner applied the enable- ment factors detailed in In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988), and discussed reasons why a skilled arti- san would not be able to make and use the claimed inven- tion without undue experimentation. J.A. 143–45. Specifically, the Examiner determined the claims were not enabled because “R” is not limited to any substituent “n” can be any number despite the closest prior art only achiev- ing a length of 8 units and the amount of direction provided

1 Claims 2, 3, 7–9, 11, 12, 14, and 15 were withdrawn from consideration due to a requirement for election of spe- cies. J.A. 87, 141. Claim 5 was also rejected as indefinite, but that rejection was reversed by the Board and not at is- sue here. J.A. 9. Case: 23-2282 Document: 45 Page: 4 Filed: 06/12/2024

4 IN RE: PEN

in the written description regarding material selection and synthetic routes was insufficient. Pen appealed to the Board. The Board affirmed the Examiner’s § 112(a) rejection. J.A. 9. In affirming, the Board noted the Examiner’s Wands factor analysis and concluded the Examiner set forth a reasonable explanation why the full scope of the claims was not enabled and Pen failed to identify reversible error. Id. at 6–9. Pen timely appeals. DISCUSSION Whether a claim satisfies the enablement requirement is a question of law that may be based on underlying fac- tual findings. Medytox, Inc. v. Galderma S.A., 71 F.4th 990, 996 (Fed. Cir. 2023) (citing Alcon Rsch. Ltd. v. Barr Lab’ys, Inc., 745 F.3d 1180, 1188, 1190 (Fed. Cir. 2014)). We review the Board’s legal conclusions de novo and its fac- tual findings for substantial evidence. In re Kotzab, 217 F.3d 1365, 1369 (Fed. Cir. 2000). “If the evidence in record will support several reasonable but contradictory conclu- sions, we will not find the Board’s decision unsupported by substantial evidence simply because the Board chose one conclusion over another plausible alternative.” In re Jolley, 308 F.3d 1317, 1320 (Fed. Cir. 2002). Section 112(a) sets forth the enablement requirement: “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the inven- tion.” 35 U.S.C. § 112(a). “If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class. In other words, the specification must enable the full scope of the Case: 23-2282 Document: 45 Page: 5 Filed: 06/12/2024

IN RE: PEN 5

invention as defined by the claims.” Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1254 (2023). In short, the more you claim, the more you must explain. I. Pen argues the Board erred in relying on precedent not cited by the Examiner and asserts the ’878 Application is factually distinguishable. We do not agree. The Board cor- rectly cited case law from this Court and the Supreme Court in explaining the enablement requirement. J.A. 7, 8 (citing Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1365 (Fed. Cir. 1997); Amgen, 143 S. Ct. at 1254). The Board also correctly set forth the evidentiary burdens for showing enablement in its citation to In re Wright, 999 F.2d 1557, 1561–62 (Fed. Cir. 1993). J.A. 7. Contrary to Pen’s allegations, the Board did not analogize to the facts of any cases to present rejections beyond those addressed by the Examiner. The Board explained the law underlying the Examiner’s rejection, which is not a new ground of rejec- tion. In re Biedermann, 733 F.3d 329, 337 (Fed. Cir. 2013) (“A new ground of rejection, however, generally will not be found based on the Board ‘further explain[ing] the Exam- iner’s rejection’ or the Board’s thoroughness in responding to an applicant’s argument.” (alteration in original) (quot- ing In re Jung, 637 F.3d 1356, 1364–65 (Fed. Cir. 2011))). Pen, however, in attempting to distinguish the cited cases, presents a new argument in this appeal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Jung
637 F.3d 1356 (Federal Circuit, 2011)
In Re Stephen E. Wright
999 F.2d 1557 (Federal Circuit, 1993)
In Re Werner Kotzab
217 F.3d 1365 (Federal Circuit, 2000)
In Re Scott T. Jolley
308 F.3d 1317 (Federal Circuit, 2002)
In Re Lavaughn F. Watts, Jr
354 F.3d 1362 (Federal Circuit, 2004)
Inre: Biedermann
733 F.3d 329 (Federal Circuit, 2013)
Alcon Research, Ltd. v. Barr Laboratories, Inc.
745 F.3d 1180 (Federal Circuit, 2014)
Medytox, Inc. v. Galderma S.A.
71 F.4th 990 (Federal Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
In Re PEN, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-pen-cafc-2024.